December 10th & 11th, 2026
15th edition
MARSEILLE, FR
Stand D23

2025 Edition

Inhatarget

Belgium

InhaTarget Therapeutics is a spin-off company from the University of Brussels (ULB) – Belgium, dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, with a first focus on lung cancer. The company was established in August 2019 and brings together strong complementary expertise in drug formulation, inhalation delivery, immunology, preclinical development and clinical operations.

Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.